Kardashian Barker discusses the brand’s latest hair growth and anti-shedding capsule launch, her current post-pregnancy hair ...

KOURTNEY Kardashian is facing backlash after being branded “shameless” over an ill-timed birthday post on Kris Jenner’s birthday. Reality star Kourtney, 45, came under fire for ...

Ads for Ozempic and other weight loss meds are everywhere. The weight loss drug biz is a $100 billion industry. I know a ...

MONDAY, Oct. 28, 2024 (HealthDay News) -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

announced statistically significant comparative data on its study of Gimoti nasal spray as a potential supportive care in diabetic gastroparesis patients using Glucagon-like peptide-1 or GLP-1.

The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists.

Fares Qeadan, PhD, from the Parkinson School of Health Sciences and Public Health at Loyola University Chicago, and colleagues evaluated the strength of the GIP/GLP-1 RA and substance use-outcome ...

Between 2022 and 2023, prescriptions for GLP-1 drugs soared 132.6% while bariatric surgery rates fell 25.6%, according to a new study from researchers at Boston-based Harvard Medical School and ...

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 ...

One of the biggest sensations fueling the healthcare space right now is the medication class of glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with the term "GLP-1," you've ...

A recent article highlights the critical importance of skeletal muscle mass in the context of medically induced weight loss, particularly with the widespread use of GLP-1 receptor agonists. These ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...